FMO6P
Putative dimethylaniline monooxygenase [N-oxide-forming] 6
Also known as: FMO6_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for FMO6P in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
539 residues, UniProt reviewed canonical sequence.
>O60774|FMO6P
1 MSKRVGIIGA GVSGLAAIWC CLEEGLEPTC FERSDDVGGL WKFSDHTEEG RASIYQSVFT
61 NSSKEMMCFP DFPYPDDYPN YIHHSKLQEY IKTYAQKKDL LRYIQFETLV SGIKKCPSFL
121 VTGQWVVVTE KDGKQESTIF DAVMICSGHH VYPNLPTDSF PGLDQFRGNY LHSRDYKNPE
181 AFKGKRVLVI GLGNSGSDIA VELSRLATQV IISTRSASWV MSRVWDDGYP WDMMYVTRFA
241 SFLRNVLPSF ISDWLYVQKM NTWFKHENYG LMPLNGSLRK EPVFNDELPS RILCGTLSIK
301 PSVKEFTETS AVFEDGTMFE AIDSVIFATG YDYSYPFLDE TIMKSRNNEV TLFKGIFPPL
361 MEKPTLAVIG LVQSLGAAIP TADLQAWWAA KVFANSCTLP TTNEMMDDTD EKMGKKLKCM
421 FSSFFMFGQS QTLQTDYITY VDELGSFIGA KPNIPWLFLT DPRLALEVYF GPCSPYQFRL
481 MGPGKWDGAR NAILTQWNRT VKPTRTRVVS EVQRPHPFYN LLKMLSFPLL LLAVTLTFYLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FMO6P can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.23
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.06
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.03
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FMO6P as an antibody target. Whether an autoantibody or antibody against FMO6P could matter depends on whether native FMO6P is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FMO6P is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label FMO6P as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...